news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

Nandu News: Recently, the signing ceremony of the cooperation agreement between China Resources Guangdong Pharmaceutical Co., Ltd. (South China Region) and Hong Kong Science Park Corporation was held at Hong Kong Science Park. According to the agreement, the two parties will establish a closer cooperative relationship, jointly explore cooperation opportunities in the development of the pharmaceutical industry in Hong Kong and even the Guangdong-Hong Kong-Macao Greater Bay Area, release the "potential energy" of innovation, and accelerate the promotion of high-quality innovation and development of the biopharmaceutical industry in the two places.

The signing ceremony was witnessed by China Resources Pharmaceutical Group, Hong Kong Innovation, Technology and Industry Bureau, Hong Kong Science and Technology Parks Corporation, leaders of the Guangdong Provincial Department of Commerce in Hong Kong, and representatives of well-known pharmaceutical industry companies.

Guo Ting, general manager of China Resources Pharmaceutical Commercial, said that as an important business unit of China Resources Group's big health sector, China Resources Pharmaceutical Commercial Group has now developed into a leading large-scale pharmaceutical distribution company in China, fully implementing the Healthy China strategy, continuously establishing and strengthening the drug and equipment supply guarantee system, relying on a nationwide network layout that reaches terminals, and building a patient-based innovative drug full life cycle management platform to continuously meet the people's growing needs for a better life.

China Resources Guangdong Pharmaceutical Company is a strategic development platform for pharmaceutical distribution established by China Resources Pharmaceutical Commercial Group in Guangdong Province and based in the Greater Bay Area. It has nearly 30 years of rich import and export experience and is the largest importer of pharmaceuticals and medical devices at the southern China port. It has long maintained strategic partnerships with multinational pharmaceutical companies and continues to provide global pharmaceutical companies with pre-market cooperation, import and export services, national distribution, terminal delivery, innovative payment and other omni-channel, one-stop services for their innovative products, so that more and better innovative drugs and medical devices from overseas can be introduced into China in a timely and early manner to benefit more Chinese patients.

As the largest technology research and development and business incubation base in Hong Kong, the Hong Kong Science and Technology Parks Corporation has more than 2,000 companies in the park. The company provides integrated support for biotechnology companies, including advanced shared laboratories, business investment network matching, entrepreneurial skills and business training and other support services.

At the ceremony, Dr. Siya Liu, Senior Director of Translational Research Institute of Hong Kong Science and Technology Parks Corporation, introduced the Hong Kong biopharmaceutical ecosystem. The strong alliance between the two parties will surely stimulate new momentum.To promote product distribution and market access cooperation among innovative pharmaceutical and medical device R&D companies in the park in the Chinese mainland market, and drive development to a new level.

At the signing ceremony, China Resources Guangdong Pharmaceutical (South China Region)General Manager Huo Peiqiong gave a speech on the theme of "Incubation, Transformation and Internationalization", and provided professional interpretation on how to release the revenue growth potential of mainland China and overseas market opportunities, and shared the "Hong Kong and Macao Drug and Equipment Access" project being implemented in Guangdong. She mentioned that the Greater Bay Area has advantages in terms of both population base and application scenarios. The "Hong Kong and Macao Drug and Equipment Access" policy varieties have been expanded to 67, benefiting more than 7,000 patients, and has entered a period of rapid development, effectively meeting the people's urgent clinical needs for drugs and equipment.

China Resources Guangdong Pharmaceutical will further leverage its international supply chain operation capabilities and national distribution strength to strengthen resource integration and complementary advantages with partners to help accelerate the implementation of related businesses.Assist mainland innovative pharmaceutical and medical device companies to create cooperation opportunities with companies of the Hong Kong Science and Technology Parks Corporation, so that good mainland products can also go overseas through Hong Kong, and realize the "dual circulation" of the Greater Bay Area's pharmaceutical and medical device international business。

On the same day, China Resources Guangdong Pharmaceutical signed letters of intent for cooperation with Silicon Biotech and InMed Medical respectively.

Written by: Southern Metropolis Daily reporter Huang Haishan

Image source: Provided by the interviewee